Zobrazeno 1 - 9
of 9
pro vyhledávání: '"N. G. Ranen"'
Autor:
Anne Elizabeth Rosser, C. K. ffrench-Constant, Russell L. Margolis, John R. Hodges, J. Leggo, Christopher A. Ross, Adam Rosenblatt, Mark W. Becher, M. Sherr, M. V. Wagster, Mary L. Franz, N. G. Ranen, O. C. Stine, David C. Rubinsztein, Margaret H. Abbott
Publikováno v:
Neurology. 51:215-220
OBJECTIVE: To describe characteristics of gene-negative patients with clinical features of Huntington's disease (HD), exploring likely etiologies. BACKGROUND: When a direct gene test became definitive for diagnosis of HD, we discovered a number of pa
Publikováno v:
The Journal of Neuropsychiatry and Clinical Neurosciences. 8:338-340
Sertraline, a selective serotonin reuptake inhibitor, was used to treat two consecutive cases of genetically confirmed Huntington's disease in which severe irritability and aggressiveness required inpatient admission. The complete cessation of aggres
Autor:
Elizabeth H. Aylward, Candace Young, Jason Brandt, Laura Krafft, Ann Marie Codori, Phillip R. Slavney, N G Ranen, Michael Magdalinski, Jeffrey R. Campodonico
Publikováno v:
Journal of the International Neuropsychological Society : JINS. 4(5)
Recent studies have detected basal ganglia atrophy in clinically asymptomatic persons with the genetic mutation that causes Huntington's disease (HD). Whether reductions in caudate and putamen volume on MRI scans are associated with changes in cognit
Autor:
M. L. Franz, P. S. Harper, Jayne Leggo, Mark W. Becher, M. Sherr, M. H. Abbott, J. C. Macmillan, L. Barron, M. Porteous, David C. Rubinsztein, O. C. Stine, M. V. Wagster, Christopher A. Ross, N. G. Ranen
Publikováno v:
Movement disorders : official journal of the Movement Disorder Society. 12(4)
Dentatorubral and pallidoluysian atrophy (DRPLA) is an autosomal dominant disorder that clinically overlaps with Huntington's disease (HD) and manifests combinations of chorea, myoclonus, seizures, ataxia, and dementia. DRPLA is caused by a CAG tripl
Autor:
Susan E. Folstein, Jason Brandt, Leslie Day, Joseph T. Coyle, Carol E. Peyser, Marshal F. Folstein, M. Sherr, Christopher A. Ross, N G Ranen, Frederick W. Bylsma
Publikováno v:
Movement disorders : official journal of the Movement Disorder Society. 11(5)
One hundred patients with clinically diagnosed Huntington's disease (HD) were randomized to either idebenone, an antioxidant and enhancer of oxidative metabolism, or placebo, in a 1-year, double-blind, parallel-group study aimed at slowing the rate o
Autor:
N G, Ranen, O C, Stine, M H, Abbott, M, Sherr, A M, Codori, M L, Franz, N I, Chao, A S, Chung, N, Pleasant, C, Callahan
Publikováno v:
American journal of human genetics. 57(3)
Huntington disease (HD) is an autosomal dominant degenerative disorder caused by an expanded and unstable trinucleotide repeat (CAG)n in a gene (IT-15) on chromosome 4. HD exhibits genetic anticipation--earlier onset in successive generations within
Publikováno v:
The Journal of neuropsychiatry and clinical neurosciences. 6(2)
The authors review the records of 6 patients with Huntington's disease (HD) who received electroconvulsive therapy (ECT) for depression. Five patients met criteria for major depression and 1 for bipolar disorder, depressed. None of the patients had r
Autor:
Russell L. Margolis, O.C. Stine, Molly V. Wagster, W.S. Young, N G Ranen, Gabriele Schilling, M.L. Franz, Christopher A. Ross, Susan E. Folstein, Xiaohai Li, Shihua Li, John C. Hedreen, M. H. Abbott
Publikováno v:
Neuron. 11(5)
Huntington's Disease (HD) is notable for selective neuronal vulnerability in the basal ganglia and cerebral cortex. We have investigated in human and rodent tissues the expression of the gene (IT15) whose mutation causes HD. IT15 is widely expressed,
Autor:
N G Ranen
Publikováno v:
Electroencephalography and Clinical Neurophysiology. 98:227